Euroscicon Conference on

Biosimilars 2019

Theme: Developmental Strategies and Uptake of Biosimilars in Pharmaceuticals Early Bird Registration is closing Soon! DO NOT MISS OUT!

Event Date & Time

Event Location

Budapest, Hungary

18 years of lifescience communication

17345684571

Performers / Professionals From Around The Globe

Conference Speaker

Klara Valko

UCL School of Pharmacy, London, UK.
UK

Conference Speaker

Dr. Pawan Saharan

CEO of Biomix Network Ltd,USA
India

Tracks & Key Topics

Biosimilars 2019

About Conference

The Euroscicon is welcoming for Conference on Biosimilars 2019 on March 25 - 26, 2019, Budapest, Hungary. The topic of the current year's gathering is Developmental Strategies and Uptake of Biosimilars in Pharmaceuticals which will give a worldwide stage to talk of present and future  of Biosimilars.The extension of two committed streams for the EuroSciCon Conference on Biosimilars 2019 gathering was a hit we could get learning from two specific gathering  one that surpassed desires in the deliberate and collecting end  and one that surpassed desires in the business and key end.

The 2019 foundation of this gathering will empower us to continue plunging further into both the examination of Biosimilar change and the business necessities for associations.

The Organizing Committee is satisfied to welcome you to attend the EuroSciCon Conference on Biosimilars, one of its astonishing Pharmaceutical gatherings to be held in the midst of March 25-26, 2019 in Budapest, Hungary. EuroSciCon Conference on Biosimilars joins scientists, authorities and CROs from around the world. With the support of second Biosimilar by the USFDA-Inflectra, the Biosimilars promote is had to experience an exponential improvement over the coming couple of years. Various Biologics things are affecting their passage in the pharma to publicise and experiencing a striking climb in their utilization over the standard remedies.

At Biosimilars 2019 meet your planned intrigue bunches from around the world focused on getting some answers concerning Biologics and Biosimilars. This gathering would be your single most obvious opportunity to accomplish the greatest accumulation of individuals from the Biologics and Biosimilars gathering.

Why to Attend?

Join your companions the world over focused on getting some answers concerning Biologics and Biosimilars related advances, which is your single most obvious opportunity to accomplish the greatest gathering of individuals from the Biosimilars society, coordinate shows, scatter information, meet with recurring pattern and potential specialists, make a sprinkle with new research works, and get name affirmation at this Two-day event. Broadly acclaimed speakers, the most recent research, moves, and the most momentum refreshes in Biologics and Biosimilars are indications of this gathering.Provision of information on new technologies implemented in the field of Biosimilars and a sound knowledge on the Clinical Trail development.Provides interaction with the world's well known CEO's and Directors of the Pharmaceutical companies.

Benefits to attend Biosimilar 2019:

a) Keynote introduction alongside connections to excite established researchers.

b) Workshop and symposiums to achieve the biggest array of members from the Pharma/Biotech people group.

c) A wide track of exhibitors to grandstand the new and rising advancements

d) Platform to worldwide speculation group to interface with partners in Pharma/Biotech area

e) Links to the political promoting assets keeping in mind the end goal to extend your business and research organize

f) Triumph of Awards, Certificates perceives your sense of duty regarding your calling to empower the incipient research.

Biosimilars 2019 Benefits:

• Open board exchanges: Providing an open gathering with specialists from the scholarly world and business to talk about on current difficulties in Biosimilars and Biologics, where all participants can collaborate with the board took after by a Q&A session.

• Speaker and notice introductions: Providing a stage to all academicians and industry experts to share their exploration contemplations and discoveries through a discourse or a publication introduction.

Editorial executive gathering: Discussing on development and advancement of open access Bioanalysis and Biomedicine International Journals and enlisting board individuals and analysts who can bolster the diary.

• Round table gatherings: Providing a stage where industry experts meet scholastic specialists.

Business and Exhibitor Benefits:

Over 50+ organizations and international pavilions will be exhibiting at the EuroSciCon Biosimilars 2019 conference. . Exhibitors will include equipment manufacturers and suppliers, systems providers, finance and investment firms, R&D companies, project developers, trade associations, and government agencies.

 In addition to the products and services you will have access to valuable content, including Keynote Presentations, Product Demonstrations and Educational Sessions from today’s industry leaders.

The EuroSciCon Biosimilars 2019 has everything you need, all under one roof, saving you both time and money.   It is the event you cannot afford to miss!

Target Audience:

• Executives, CEO's of Organizations

• Business Development Managers

• Boss Scientific Officers

• Research and development Researchers from Biosimilar and Biologics Industries

• Educators, Associate Professors, Assistant Professors

• PhD Scholars

• Patent Attorneys

• Protected innovation Attorneys

• Speculation Analysts

•Affiliation, Association presidents and experts

• Honourable laureates in Health Care and Medicine

• Bio instruments Professionals

• Bio-informatics Professionals

• Programming improvement organizations

• Research Institutes and individuals

• Inventory network organizations

• Assembling Companies

• CRO (Contract Research Organization) and DATA administration Companies

• Preparing Institutes

• Business Entrepreneurs

About Venue:

Budapest is the capital and the most crowded city of Hungary, and one of the biggest urban areas in the European Union. Budapest is a main worldwide city with qualities in trade, fund, media, craftsmanship, and look into, innovation, training, and stimulation. More than 40 schools and colleges are situated in Budapest, including the Eotvos Lorand University, Semmelweis University and Budapest University of Technology and Economics, which have been positioned among the best 500 on the planet. Budapest positioned as the most liveable Central and Eastern European city on EIU's personal satisfaction file. Budapest is referred to as a standout amongst the most delightful urban communities in Europe, positioned as "the world's second best city" by Conde Nast Traveler. Budapest has a marginal muggy mainland atmosphere, with moderately icy winters and warm summers.

Tracks and Sessions

Scope of Biosimilars in Therapeutics

Biosimilars Market is encountering a development at an exponential rate. By and by around 700 Biologics are gaining ground in the examination pipelines of almost 250 Biopharma organizations. Biosimilars have just begun up setting the future medication advancement in the domain of Oncology.The European Medicines Agency (EMEA) strongly supports the concept of Biosimilar drugs, and has set regulatory guidelines for the development and testing of Biosimilars. Europe is currently the region with highest availability of approved Biosimilars.

  • Biosimilars for Cancer Treatment
  • Biosimilars for Immune Disorder Treatment
  • Monoclonal Antibody Biosimilars
  • Erythropoietin Biosimilars
  • Conceptual Development of Biosimilars

Legal Consideration for Biosimilars

For almost few decades, drug specialists have been administering bland medications inside the bounds of existing laws. The current rise of Biosimilars asks for a comprehension of nonexclusive equivalency controls and how Biosimilar medicines may fit into existing laws or what changes might be important to enable drug specialists to administer these new elements, with the objective of sparing millions or even billions of dollars simultaneously.

  • Generic Drugs
  • The Purple Book
  • Safety and Risk Management Pharmacovigilance
  • Naming of Biosimilars
  • Market Access

Biosimilars Development Programme

Expository, preclinical and clinical pharmacokinetic/pharmacodynamic examines show that the dynamic substance in the Biosimilar solution coordinates the reference prescription. Last affirmation of Biosimilarity requires a clinical Phase III corroborative wellbeing and viability think about in a touchy sign. Both methodologies furnish a similar level of certainty with respect to wellbeing and adequacy of the natural drug.

  • Approval Process for Biosimilar Products
  • Integrated Approach for Biosimilar Development
  • Clinical Trial Design
  • New Trends in Delivery Systems
  • Improving the Drug Performance

Biosimilar Analytical Methods

Investigation of Biosimilars and Biologics structures to be a standout amongst the most essential perspective towards the Biologics and Biosimilar improvement process. Biosimilars scientific techniques for process improvement, approval and additionally utilization of creation advances, for example, disposables and store network coordination can help organizations to set up adaptability.

  • Establishing Biosimilarity
  • Bioactivity / Potency Testing
  • Assessment of Biosimilarity
  • Process Related Impurities
  • GMP Protein Analysis

Biosimilar Interchangeability

Biological products are the fastest-growing class of therapeutic products in the world. When patients are prescribed a Biological product, Biosimilar and interchangeable products can offer additional treatment options, potentially lowering health care costs.

  • Biological Products
  • Biosimilar Products
  • Approval Standards for Interchangeable Products
  • Enhancing the Treatment Procedures

Monoclonal Antibody Biosimilars

Monoclonal antibodies (mAbs) are natural specialists that are broadly used to treat malignancies including non-Hodgkin's lymphomas and ceaseless lymphocytic leukaemia. They are compelling however costly. The licenses for some, mAbs are lapsing, so Biosimilar solutions, which contain an adaptation of the dynamic element of the first medication, are being produced.

  • Monoclonal Antibodies in Oncology
  • Lymphatic Disorder Treatment
  • Rheumatoid Arthritis Treatment
  • Guidelines for Monoclonal Antibody Production

Globalization of Biosimilars

This track plates about the non-specific medications effect on worldwide Biosimilar showcase, Cost and hazard administration, Adopting creative systems, for example, chance sharing plan, European market for Biosimilars. The worldwide market situation with the dispatch of first Biosimilar in the market estimates some radical changes. This track will view such key concerns which are seen by the worldwide pharma showcase and that are thinking of the consequent dispatch of alternate Biosimilars and Biologics. Despite these rising offices, bio therapeutic designers are most agreeable off-shoring to set up business sectors.

  • Biosimilar Multimodal Techniques
  • Biosimilar Electrophoresis
  • Biosimilar Formulation
  • Biosimilar GMP Protein Analysis
  • Supply Chain Challenges Before Biosimilars

Biosimilar Research Pipeline

Biosimilars is a Biologic therapeutic item which is duplicate of a unique item that is made by an alternate organization. Biosimilars are formally affirmed creative adaptations of unique items, and can be made when the first item's patent terminates. Reference to the trailblazer item is a necessary segment of the endorsement. This session likewise discovers put for all the Biosimilar exhibitors related with the field of Biosimilar and Biologics.

  • Biosimilars in Global Market
  • Economic Aspects Towards Biosimilars
  • Cost and Risk Management
  • Global Impact of Biosimilars Over Generics
  • Monitoring the Production of Biological Products
  • Assessment of Quality

Current  Trends in Pharmaceutical  Industry

This track discusses about the new techniques and innovation of Biosimilar drugs that play a major role in pharmaceutical industry in reducing the cost of manufacturing and lowering the risk of side effects and maintaining the quality.It discusses about the new Biosimilars developed and their action upon the target diseases.It relates to the rise of production of Biosimilars around the world.

  • Purpose and Principles of GMP
  • R&D and Way to Innovation of New Medicines
  • Pharmaceutical Process Validation
  • Regulatory Requirements

Bioequivalence Assessment

Bioequivalence centres around the equality of arrival of the dynamic pharmaceutical fixing from the pharmaceutical item and its resulting assimilation into the fundamental flow. This session has most extreme significance in setting to the way that lone an appropriately bioequivalent sedate competitor that adjusts the outcomes in all regards to the first authorized item can be called as Biosimilar tranquilize.

  • Strategies for the Bioequivalence Assessment of Topical Dosage Forms
  • Evaluation of Highly Variable Drugs and Drug Products
  • Bioequivalence Approaches for Transdermal Dosage Forms
  • Bioequivalence Assessment of Respiratory Dosage Form

Brexit Effect on  Biosimilars

The Brexit impact on Biosimilars has a tendency to be negative. In addition to the fact that it would be a noteworthy mishap towards endorsement and dispatch of Biosimilars to the market yet additionally it would be deterrent towards the cost cutting methodology taken up by NHS. With Britain being among chief clinical trial focuses is possessed to see a reduction in the ability of the makers and specialists to complete any further trials in Britain.

  • Brexit Pros and Cons to European Pharma Market
  • Post Brexit Changes in Biosimilar Regulation in UK
  • Fate of Biosimilars Clinical Trials in UK

Clinical Adavancement of Biosimilars

This track incorporates Clinical trials on significant maladies Risk administration, and quality issues, Case thinks about, and clinical models, Transgenic creatures, Targeted cell line advancement, Clinical Biosimilar tracks.docx PK/PD examines, Toxicological investigations and Aspects of genotoxicity tests. Clinical trials are planned in stages I-IV in order to get a reasonable photo of the medication applicant in regard to its pharmacokinetics and pharmacodynamics parameters.

  • Aspects of Genotoxicity Tests
  • Biosimilars Clinical Studies
  • Case Studies and Clinical Models
  • Toxicological Studies
  • Transgenic Animals

Intellectual Property Rights

The defending of item competitive advantage, its plans and different process parameters by law is generally secured by IPR. It incorporates those as licenses, copyrights, mechanical outline rights, trademarks and so forth. IPR is of prime significance in the field of Biologics and Biosimilars. Most researcher and enterprises have a tendency to hold their restraining infrastructure business by practicing the IPR.

  • Critical Research Issues
  • Patentable Subject Matter
  • Criteria for Patentability and Patent Claim
  • Pharma Patent Scenario

Challenges in Biosimilar  Pharmacovigilance

This session of the Biosimilars 2019 will investigate the future and FDA activities that have just been reported to incorporate upgraded following and follow-up of post showcasing reconnaissance issues, arranged enhancements in AERS, and pilots of new post advertise sedate observing procedures and ADR related issues. Biosimilar rules for pharmacovigilance practice and pharmacoepidemiology are the focuses that might be laid accentuation in this session.

  • Role of Pharma Industries in the Improvement of Pharmacovigilance System
  • Current Problems in Biosimilar Pharmacovigilance
  • Detection and Evaluation of Drug Safety Signals
  • Adverse Drug Reactions with Pharmaceutical Products
  • Pharmacoepidemiology and GMP

BCS and IVIVC Biowaivers 

The goal of this work was to propose the biowaivers capability of biopharmaceutical arrangement framework which are known to expand the solvency, disintegration, oral assimilation of water insoluble medications. Biopharmaceutics Classification System and invitro and invivo characterization examines about ADME pathways of various medications. This additionally incorporates BCS biowaivers, In vitro dispersion cells for disintegration testing in definition improvement, In vitro preclinical ADME/BCS testing.

  • Consideration of Biowaiver Extensions for BCS Class III Drugs
  • Dissolution Testing in Drug Formulation
  • In Vitro Preclinical ADME/BCS Testing
  • In Vitro Drug Product Research

Enhancing Drug Delivery System

Floor covering Delivery Companies and Market session is starting to change for little, medium, and huge scale pharmaceutical Co, biopharmaceutical Manufacturing and Industries, non-specific medications organizations, contract sedate conveyance organizations which can show from improvement to assembling. Tending to these insecurities is an extraordinary test, on account of the many-sided quality of the Clinical bio therapeutics themselves.

  • New Approaches to Enhance Drug Performance.
  • Drug Delivery Companies and Markets
  • Drug Delivery Companies and Market  Strategies
  • Drug Delivery Technologies

Legal  Issues and BPCI Act

The lawful issues relating to the take after on-Biologics and Biosimilars are a standout amongst the most perspectives that requires an open exchange. Before the real appearance of Biosimilars to the market lawful issues have ascended in numbers in their formative stages. Prestigious associations have recorded bodies of evidence against each other two case their rights and for other lawful assertions identified with the items. This track is committed to talk of every single such case which has been contended in the courtroom.

  • Market Exclusivities
  • Patent Negotiation and Litigation Phase
  • Patent Protection and Infringement Issues

Biopharmaceuticals

Unique in relation to completely integrated pharmaceuticals, they incorporate immunizations, blood, blood segments, allergenics, substantial cells, quality treatments, tissues, recombinant helpful protein, and living cells utilized as a part of cell treatment. Biologics can be made out of sugars, proteins, or nucleic acids or complex blends of these substances, or might live cells or tissues.

  • Biopharmaceutical Research
  • Recombinant Protein Expression
  • Monoclonal Antibodies

Entrepreneurs  Investment Meet

Business visionaries who will put in diligent work and put resources into the field of Biologics and Biosimilars will discover this gathering the best place to legitimately shape their drive for the new undertakings. Likewise this gathering will enable them to locate the best specialists who can make their venture productive and beneficial.

  • Biologics Ruling the Market
  • Brand Biologics
  • Growth of Biologics

Biosimilars Companies and Market  Analysis

The EU represents 22 percent of the market's business esteem and 14 percent of its esteem development. Conversely, developing markets speak to only a fragment of the business pie, with 7.5 percent share. Consequently, Biologics showcase development is still to a great extent driven by develop markets. The worldwide Biologics advertise had come to $170 billion in deals an incentive in 2012, representing 18 percent of the general market.

  • Biosimilars Europe
  • Rise in Biosimilar Use                      
  • Contribution of Biosimilars in Global Market

Quality  Assessment for  Biosimilars

Expository information submitted ought to be to such an extent that firm conclusions on the physicochemical and organic comparability between the reference restorative item and the Biosimilar can be made.

  • GMP Guidelines
  • Demonstration Equivalence in Contrast to Non-Inferiority
  • Importance Of Similarity On The Quality Levels

In vivo Studies of  Biosimilars

This track describes about the use of Biosimilars in in vivo studies and their Importance in estimating their therapeutic importance and activity. In September 2013 the first Biosimilar mAb, infliximab, was authorised in Europe.

  • Non-Clinical in Vivo Studies
  • Development of Unmarked Biosimilars
  • Minimisation of Unnecessary Use Of Animals
  • Toxicology Studies

Global  Markets  for  Erythropoietin  Biosimilars

The worldwide erythropoietin Biosimilars medicate showcase has been developing quickly in the previous decade, principally because of the patent expiry of significant erythropoietin Biologic medication in European market.

  • Growth of Erythropoietin Biosimilar Drug Market
  • Erythropoietin Stimulating Agents
  • Erythropoietin Biosimilars for Anaemia Treatment
  • Cloning of Genes for Erythropoietin Biosimilars

Biosimilar Switch

Biological disease-modifying antirheumatic drugs (bDMARDs) have revolutionised the therapeutic management of inflammatory rheumatic diseases with dramatic clinical improvement and reduction in systemic inflammation in arthritis.

  • Reasons of Switching
  • Immunogenicity
  • Switching of bDMARD to its Biosimilars
  • Switches in Clinical Trails

Biological Products

This track discusses means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein or analogous product, or arsphenamine or derivative of arsphenamine, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

  • Biosimilar Biological Products
  • Conceptual Development of Biosimilars
  • Drug Designing

Learn More

Top Biosimilar Universities all over the world:

Harvard University |  University of Cambridge |  University of California, San Francisco |  University College London |  University of North Carolina |  Karolinska Institute |  Yale University |  King's College London |  University of California, San Diego |  Cardiff University |  Stanford University |  The Imperial College of Science, Technology and Medicine | The University of Manchester |  The University of Texas |  Utrecht University |  The University of Dundee |  Columbia University | Monash University |  University of Oxford |  Pierre and Marie Curie University |  Medical University of Vienna | Rockefeller University | Uppsala University | University of Pennsylvania | University of Zurich | University of Tuebingen | The Ohio State University | Radboud University Nijmegen| Norwegian University of Science and Technology | Vanderbilt University | McGill University | University of Hamburg | University of Lausanne | University of Paris Descartes  | The University of Tokyo | University of California, Berkeley | Swiss Federal Institute of Technology Zurich | Kyoto University | University of Wisconsin – Madison | University of Arizona | University of South Florida | University of Utah | China Pharmaceutical University.

Biosimilar Universities in UK:

Aston University | Cardiff University| De Montfort University| Keele University| King's College London| Kingston University| Liverpool John Moores University| Queen's University Belfast| Robert Gordon University| University of Bath| University of Bradford| University of Brighton| University of Central Lancashire| University College London| University of East Anglia| University of Greenwich/University of Kent| University of Hertfordshire| University of Huddersfield| University of Lincoln| University of Manchester| University of Nottingham| University of Portsmouth| University of Reading| University of Strathclyde| University of Sunderland| University of Sussex| Ulster University| University of Wolverhampton.

Biosimilar Universities in USA:

University of Southern California | CUNY York College | Purdue University | University of Wisconsin-Madison | Albany College of Pharmacy and Health Sciences | University of North Carolina | University of Colorado | Oregon State University | Nova Southeastern University | Massachusetts College of Pharmacy and Health Sciences | University of Florida College of Pharmacy | University of Michigan College of Pharmacy | Campbell University School of Pharmacy | University of Pittsburgh School of Pharmacy | University of Georgia College of Pharmacy | Temple University School of Pharmacy | Ernest Mario School of Pharmacy | Skaggs School of Pharmacy | Eugene Applebaum College of Pharmacy and Health Sciences | University of North Carolina | University of Minnesota | University of California—San Francisco  | University of Michigan—Ann Arbor | University of Texas—Austin | Ohio State University | University of Illinois—Chicago | University of Kentucky | Purdue University | University of Florida | University of Maryland—Baltimore  | University of Pittsburgh  | University of Southern California | University of Washington| University of Wisconsin—Madison | University of Arizona | University of Iowa | University of Tennessee Health Science Center | University of Utah | University of Kansas | Virginia Commonwealth University | University at Buffalo | University of Colorado—Denver | Auburn University  | University of California—San Diego | University of Oklahoma | Northeastern University .

Biosimilar Universities in Asia:

University of Tokyo | National University of Singapore | Kyoto University | University of Hong Kong | Peking University | Seoul National University | National Taiwan University  | Osaka University | Tsinghua University | Chinese University of Hong Kong | Fudan University |The Hong Kong University of Science and Technology | Taipei Medical University |Mahidol University | Korea Advanced Institute of Science and Technology | Yonsei University |Shanghai Jiao Tong University | Nanyang Technological University | Chulalongkorn University | Tohoku University | Tokyo Medical and Dental University | Kyushu University |Nagoya University | Hokkaido University |Sungkyunkwan University | University of Science and Technology of China | Pohang University of Science and Technology | Korea University | University Malaya  | Indian Institute of Science.

Biosimilar Universities in Africa:

Batna  University | University of Kinshasa  |  University of Lubumbashi | Ahram Canadian University | Alexandria University | British University in Egypt | Cairo University | German University in Cairo | Helwan University | Kafrelsheikh University | Mansoura University | Nahda University | Pharos University in Alexandria | Suez Canal University | Tanta University | Zagazig University | Addis Ababa University | Wollega University | Kwame Nkrumah University of Science and Technology | Kenya Methodist University | Kenyatta University | Elmergib University | University of Benghazi | University of Zawia | University of Misurata | University of Rwanda | Nelson Mandela Metropolitan University | North-West University | Rhodes University | University of KwaZulu | University of Limpopo | University of Pretoria | University of the Western Cape | University of the Witwaters | Ahfad University for Women | University of Khartoum | Omdurman Islamic University | Catholic University of Health and Allied Sciences | Kampala International University | Muhimbili University of Health and Allied Sciences | St. John's University of Tanzania | University of MonastirMakerere University | Mbarara University of Science and Technology| University of Zambia | Harare Institute of Technology | University of Zimbabwe.

Biosimilar Societies:

Societies in Europe: Belgian Society of Pharmaceutical Sciences (BGFW), European Federation for Pharmaceutical Sciences (EUFEPS), Italian Society for Pharmaceutical Sciences (SISF), Association of the British Pharmaceutical Industry (ABPI). A Division of the Association for Accessibility medicines (DAAM), European Biopharmaceutical Trade Association, Biosimilars - Generic Pharmaceutical Association, European Generic medicines Association.

Societies in USA: Canadian Society for Pharmaceutical Sciences (CSPS), Pharmaceutical Manufacturers Association of Canada (PMAC), American Association of Pharmacy Technicians (AAPT), American Society of Health-System Pharmacists (ASHYP). Canadian Society of Intestinal research (CSIR)                                                                                                                                                        

Societies in Asia and Pacific: The Pharmaceutical Society of Australia (PSA),  Austrian Pharmaceutical Society (APS), Korean Research-based Pharmaceutical Industry Association (KRPIA), Kuwait Pharmaceutical Association (KPA).

Conferences Related to Biosimilars all over the world:

5th  International Conference on Advanced Clinical Research and Clinical Trials, September 10-11, 2018 at Zurich, Switzerland| 9th  International Conference and Expo on Separation Techniques, September 13-14, 2018 at Zurich, Switzerland| 8th  International Conference on Environmental Chemistry and Engineering, September 20-22, 2018 at Berlin, Germany| 7th  International Conference and Exhibition on Pain Research and Management, October 11-12, 2018 at Zurich, Switzerland| 18th World Pharma Congress, October 18-20, 2018 at Warsaw, Poland|  4th  International Conference on Drug Discovery and Advanced Drug Delivery Systems & Technologies, October 18-19, 2018 at Warsaw, Poland| 18th  Annual Pharmaceutical Chemical Analysis Congress, November 05-06, 2018 at Madrid, Spain| 9th Global Experts Meeting on Neuropharmacology, November 15-16, 2018 at Frankfurt, Germany| 3rd  International Conference on Generics Drugs and Biosimilars, November 15-17, 2018 at Frankfurt, Germany| 23rd  International Conference on Pharmaceutical Biotechnology, December 10-11, 2018 at Rome, Italy| 5th  Annual conference on Biosimilars| Biosimilars Global Congress 2014 Europe| EGA International Biosimilar Medicines Conference| World Biosimilars Congress| 3rd  Annual Biosimilars & Biobetters Congress 2015| 6th  Annual Biosimilars ASIA| 10th  Annual Summit on Biosimilars| European Biosimilars Congress April 26-27, 2018 Rome, Italy | Asian Biologics and Biosimilars Congress August 20-21, 2018 Tokyo, Japan | Biosimilars Summit January 23-24, 2018 Alexandria, USA | Biopharma Ambition February 21-22, 2018 Dublin, Ireland| 13th International Conference on Biologics and Biosimilars| 12th European Biosimilar Congress|  5th  Annual conference on Biosimilars| Biosimilars Global Congress 2014 Europe| EGA International Biosimilar Medicines Conference| World Biosimilars Congress| 3rd Annual Biosimilars & Biobetters Congress 2015| 6th  Annual Biosimilars ASIA| 10th  Annual Summit on Biosimilars.

Biosimilar Pharmaceutical Companies Around the World:

Hospira (Pfizer)|  Mylan| Sandoz (Novartis)| STADA ArzneimittelTeva Pharmaceutical Industries| 3SBio| Beijing ShuangLu Pharmaceutical Co.|  Qilu Pharmaceutical| Shanghai Fosun Pharmaceutical Group| Tonghua Dongbao Pharmaceutical Co.| Biocon|  Dr. Reddy’s Laboratories| Intas BiopharmaceuticalsRanbaxy (Sun Pharma)Reliance Life Sciences|  Wockhardt|  Zydus Cadila|  Amega Biotech|  Biosidus|  Probiomed|  Biocad| Bioton|  Celltrion|  Dong-A|  LG Life Sciences.

Jobs Related to Biosimilars Around the World:

Member of Regulatory Affairs| Biosimilar Account Manager, US Biosimilars| Marketing Senior Manager, Value and Access - Oncology Biosimilars| Senior Bio analytical Scientist, Analytical Lead, Biosimilars-Pfizer, Amgen| Marketing Associate Biosimilars job at Amgen| Marketing Manager Biosimilars - Oncology job at Amgen| senior director regulatory affairs| Medical & Scientific Liaison – Biosimilars| Regulatory CMC Consultant (Biosimilars)| Biosimilars in Cancer Care| European Regulatory Roundup| EuropaBio Guide on Biosimilars| Biosimilars in oncology| Regulatory Manager Biosimilar| US Biosimilars Market Development Lead-Pfizer| Senior Director Project Management Biosimilars Biotech| Biosimilars Portfolio Rep (SHR) - PEH - New York City| Medical Science Liaison- Biosimilars| Director, Immunology/Biosimilars| Medical Science Liaison, Biosimilar - AZ/NV-Sandoz| Director, Global Team.

Media Partners/Collaborator

A huge thanks to all our amazing partners. We couldn’t have a conference without you!

Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker

Sponsors/Exhibitors

A huge thanks to all our amazing partners. We couldn’t have a conference without you!